Gemeni Therapeutics is a clinical-stage precision medicine company developing therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). Co.'s lead product candidate, GEM103, is a recombinant form of the human complement factor H protein and is designed to address complement hyperactivity and overall dysregulation caused by loss of function mutations thus restoring retinal health in patients with AMD. We show 9 historical shares outstanding datapoints in our GMTX shares outstanding history coverage, used to compute GMTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GMTX market cap history over the course of time is important for investors
interested in comparing GMTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GMTX versus a peer is one thing; comparing
GMTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GMTX can fluctuate over the course of history.
With this page we aim to empower investors researching GMTX by allowing them to research the GMTX market cap history. |
Free GMTX Email Alerts:
Video: The Importance of Market Cap
